About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Friday, September 22nd, 2017

The QualityStocks
Daily Stock List


Net Medical Xpress Solutions, Inc. (NMXS)

AMIStockReports, Hawk Associates, SmallCapVoice, and Lions of Wall Street reported earlier on Net Medical Xpress Solutions, Inc. (NMXS), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Net Medical Xpress Solutions, Inc. is a leader in the telemedicine field. The Company specializes in Web-based medical solutions.  It provides telemedicine programs for diagnostic and clinical medical services. It provides these to mobile companies, urgent cares, and hospitals, trauma centers, imaging centers, jails, nursing homes, corporate health departments and outpatient medical facilities. Net Medical Xpress Solutions is headquartered in Albuquerque, New Mexico.  

Through its Net Medical Xpress Services, doctors read X-Rays, CT Scans, Ultrasounds, EKGs and more for its clients. Net Medical Xpress provides collaborative tools for quality and secure digital consultations. Being web-based and easy to learn, DICOM files such as X-Rays, Ultrasounds, CTs, MRIs, Echocardiograms, and EKGs are quickly sent and reports returned.  

Net Medical Xpress Solutions has its Telemed Building Blocks technology. This technology allows healthcare facilities to set up their own customized telemedicine infrastructure platforms. The Building Blocks technology represents the Company’s most expansive technology launch ever. 

The Company designed and built modules include Video Conferencing; Digital Paper Application; Records Server Management; Customer Scheduling; and Forms Editor. In addition, they include Secure Chat; Diagnostic Report Builder; Provider Cloud Adapter; Net Medical Santa Fe Linux Operating System; and Net Medical Open Source Linux Database. 

Net Medical Xpress Solutions has partnered with eazyScripts, an electronic prescription platform, to provide electronic prescribing services to patients remotely, through telemedicine physicians who serve populations throughout the nation. The eazyScripts platform provides telemedicine physicians with the ability to submit electronic prescriptions, check prescription fill data, and secure electronic prior authorization at the touch of a button, decreasing inefficiencies and errors. 

The Company’s partnership with the University of New Mexico (UNM) is expanding. It is working with the University’s Center for Telehealth to enhance coverage in critical care and Child Ready, a pediatric emergency medical service for rural hospitals in New Mexico, Washington, Wyoming, Minnesota and Oklahoma designed to lessen child mortality.

It is providing technology for many of UNM’s telemedicine programs. This includes cardiology, diabetes management, dermatology, burn care, psychiatry, palliative care, wound care, obstetrics and primary care for in-patients as well as ambulatory and clinical patients.
Net Medical is preparing to deploy new clinical software to provide reassurance to patients recovering from stroke and dealing with other neurological conditions. The aim is for a rural hospital’s providers to be able to assure patients that a return trip to the emergency room may not be required after being discharged. Doctors will visit through telemedicine with patients as they recover at home. This is important medically for the patients, and also financially for the insurance companies and the hospitals.

Net Medical Xpress Solutions, Inc. (NMXS), closed Friday's trading session at $0.0751, even for the day, on 91,061 volume with 18 trades. The average volume for the last 60 days is 45,325 and the stock's 52-week low/high is $0.0951/$0.3438.

Cardiff International, Inc. (CDIF)

007 Stock Chat, PennyStockSpy, Blaque Capital Stocks, DSR News, PHUB News, Juicy Penny Stocks, Wall Street Mover, CustomerService, SmallCapVoice, FivedollarMovers.net, PennyStockLocks, ResearchOTC, StockRockandRoll, PennyStockLocks, Equity Observer, Value Penny Stocks, StockBomb, StockLockandLoad, PennyStocks24, Email Stock Picks, JackpotStock Picks, PennyStock MarketBulls, PennyStock PayCheck, RagingStock Bull, Super Hero Stocks, and Xtreme Stock Picks reported earlier on Cardiff International, Inc. (CDIF), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Cardiff International, Inc. is a holding company taking advantage of proven management in private companies, which become subsidiaries under the Cardiff umbrella. Cardiff targets acquisitions of mature, high growth, niche companies. Its focus is not industry or geographic-specific. Its focus is on proven management, market, and margin. Cardiff International is headquartered in Fort Lauderdale, Florida.

The Company’s strategy identifies and empowers select income-producing middle market private businesses, technology companies, and commercial real estate properties. Cardiff International provides these companies the enhanced ability to raise money for operations or expansion, and an equity exit and liquidity strategy for the owner, heirs, and/or investors. For investors, the Company provides a diversified lower risk to protect and safely enhance their investment through continually adding assets and holdings.

In May 2017, Cardiff International announced that it signed a Letter of Intent (LOI) agreement under which MedicaMetrix will merge into Cardiff International as its subsidiary, MedicaMetrix, Inc.  MedicaMetrix is the creator of ProstaMetric®. This is a medical device for more effective prostate cancer diagnosis and monitoring with regulatory approval (CE Mark – October 2016).
This merger provides Cardiff International entry into the medical device field. 

Cardiff International, NMS Capital Group (NMS), and Prolific Media Holdings have all signed an LOI agreement. With this agreement, all parties have created Red Room Capital (RRC). This is a private equity fund focused on investments within the entertainment, media, as well as technology industries. RRC will provide investors access to marquee high profile movies, TV shows, media distribution, and new technology related industries. 

Prolific Media Holdings is an all-in-one solution for astute brands in Media and Entertainment. Prolific Media has operations ranging from Augmented Reality and Immersive Entertainment to Studio Film Co-financing, Music and Event Production. NMS Capital Group, LLC/NMS Equity Partners, LLC, is a leading international focused investment firm. It has investments in businesses across numerous asset classes. 

Cardiff International, Inc. (CDIF), closed Friday's trading session at $0.0571, even for the day, on 2,000 volume with 1 trade. The average volume for the last 60 days is 46,424 and the stock's 52-week low/high is $0.04/$0.50.

Micromem Technologies, Inc. (MMTIF)

SmallCapVoice, Xtremepicks, OurHotStockPicks, Stock Stars, and PennyStocks24 reported earlier on Micromem Technologies, Inc. (MMTIF), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Micromem Technologies, Inc. is a leader in viable Sensor Technology and MRAM (Magnetoresistive Random Access Memory). Currently, the Company is centered on magnetic sensor applications through its wholly-owned subsidiary, Micromem Applied Sensor Technologies, Inc. (MAST, Inc.). OTCQB-listed, Micromem Technologies is headquartered in Toronto, Ontario.

The Company’s MAST, Inc. subsidiary focuses on developing and marketing the delivery of innovative magnetic sensor applications in industries including Defense, Life Sciences, Automotive, Consumer, and Mining. Micromem’s technologies and solutions include surface functionalization of magnetic nanoparticles; nanoparticle detection platforms to sub-ppb detection levels; customized integration of NEMS/MEMS sensor platforms; magnetic sensor solutions; and sensor-based analytical solution platforms.

Technologies and solutions also include structural integrity sensors; wireless suib-surface power solutions; asset protection sensor platforms; and energy storage solutions. Micromem Technologies designs, develops and provides sensors specific to industry requirements.

The MAST, Inc. subsidiary is headquartered in New York, New York. MAST develops MEMS/NEMS solutions through combining disparate sensor modalities to create solutions for clients’ problems. MAST is not a product company. MAST works closely with its clients during development to ensure a smooth transfer to their production facility.

Regarding Energy Storage Solutions, MAST, working together with an energy storage company and a top U.S. utility, is providing sensor technology and overall system and product integration management for the practical realization of a new energy storage system. This system will enable lower costs than building new power generating plants.

Concerning its Magnetic Nanoparticle Detection Platform, MAST, working with a leader in the oil industry, has developed an instrument that detects breakthrough water in production oil wells via magnetic and optical sensor techniques.

This past June, Micromem Technologies, by way of its subsidiary Micromem Applied Sensor Technologies (MAST), announced it released for routine sale the RT-Lube Analyzer. This is the first in the world instrument platform capable of real time, on site detection of wear elements in lubricating fluids.

The Company’s initial emphasis is early indication of problems occurring on wind turbine gear boxes, which lead to unscheduled and expensive downtime. In the wind turbine area, particle analyzers and vibration sensors are effective at alerting failures as they take place. The RT-Lube Analyzer measures multiple wear elements in lubricants. It predicts that a failure is pending soon enough to allow operators to island the turbine and schedule the repairs.

Micromem Technologies, Inc. (MMTIF), closed Friday's trading session at $0.13, up 4.00%, on 91,061 volume with 18 trades. The average volume for the last 60 days is 45,325 and the stock's 52-week low/high is $0.0951/$0.3438.

Cerebain Biotech Corp. (CBBT)

Greenbackers, Viral Stocks, and Wall Street Mover reported earlier on Cerebain Biotech Corp. (CBBT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cerebain Biotech Corp. focuses on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution. A development-stage medical device enterprise, the Company formerly went by the name Discount Dental Materials, Inc. It changed its corporate name to Cerebain Biotech Corp. in June 2014. Cerebain Biotech is based in Costa Mesa, California. The Company lists on the OTC Markets Group’s OTCQB.

The Company’s technology has allowed for the development of a medical device, which can be implanted using a minimally invasive procedure. Upon implantation, through what will most likely be a same-day surgery procedure, patients may not have to undergo surgery again using this treatment method.

Cerebain Biotech’s device leverages the clinically observable, positive impact that omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer’s disease. Its patent-pending device is implanted in the omentum.

The omentum is a protective layer of skin that protects the abdominal organs. The design of the device is to stimulate the omentum in patients with Alzheimer’s disease. Omental stimulation has been shown to improve cognitive function in patients with dementias, including Alzheimer’s disease.

The Company’s intention is to seek Food and Drug Administration (FDA) approval in association with the development and testing of its medical device for the treatment of Alzheimer’s and Dementia. Cerebain has reached a decisive point in its research and is planning to begin development of the device. It has signed a Memorandum of Understanding (MOU) with the Department of Neurodegenerative Diseases, Mossakowski Medical Research Centre in Poland. The purpose of the MOU is to commence testing of Cerebain’s Medical Device upon completion of development.

Current plans for the Company include allocating resources to facilitate its FDA strategy as it relates to further research and testing of its existing technology. Furthermore, plans include designing a surgical manual to be used by doctors and clinicians for implanting Cerebain’s medical device.

The Company will also provide additional administrative and financial support to its scientists to leverage their time to advance Cerebain’s technologies as it nears clinical trials.

In March 2017, Cerebain Biotech announced that it engaged NMS Capital Advisors, LLC (NMS) as its financial advisor. NMS is a foremost internationally focused investment banking and advisory firm. NMS provides an assortment of Global Capital Advisory™ services that include M&A, Investment Banking, Corporate Finance and Strategic Advisory services to public and private clients in the U.S., Asia, and Europe.

Cerebain Biotech Corp. (CBBT), closed Friday's trading session at $0.29, up 3.57%, on 6,240 volume with 9 trades. The average volume for the last 60 days is 7,814 and the stock's 52-week low/high is $0.1014/$1.10.

Flux Power Holdings, Inc. (FLUX)

Penny Stock Pick Alert, Penny Stock Pick Report, PennyPickAlerts, PennyStockMoneyTrain, RisingPennyStocks, StockMister, Marketbeat.com, The Wall Street Transcript, Stock News Now, PennyStocks24, Tip.us, Catalyst IR, Joe Penny Stocks, Liquid Tycoon, Super Hot Penny Stocks, Super Nova Stock Picks, WePickPennyStocks, Winning Penny Stock Picks, Lebed.biz, Wall Street Grand, and Greenbackers reported earlier on Flux Power Holdings, Inc. (FLUX), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Flux Power Holdings, Inc. is a developer of advanced lithium batteries for industrial applications. This includes its first-ever UL 2771 Listed lithium-ion "LiFT Pack" forklift batteries. The Company develops and markets advanced lithium-ion energy storage systems (batteries) founded on its proprietary battery management system (BMS) and in-house engineering and product design. OTCQB-listed, Flux Power Holdings is based in Vista, California. 

Flux’s storage solutions deliver improved performance, extended cycle life, and greater return on investment (ROI) than legacy solutions. The Company’s products include advanced battery packs for motive power in the lift equipment, tug and tow, and robotics markets, portable power for military applications, and also stationary power for grid storage.  

Applications include Motive Power, Portable Power, and Stationary Power. Motive Power includes Lift Pack - Class III Walkie Trucks and Lift Pack - Tug & Tow Pack. Pertaining to Portable Power, Flux Portable Packs consist of lithium-ion battery cells that are managed and operated by its proprietary Battery Management System (BMS), all contained in lightweight, strong, and easily maneuvered cases. 

The design of Flux Power’s LiFT Pack solution is for walkie pallet jack forklifts, extensively utilized in warehouses and depots, on trucks, and at retail locations. The Company has developed a 72 volt, 400 Ah battery pack to power electric aviation ground support equipment, initially baggage tow tractors using the same proprietary technology found on the LiFT Pack line for small forklifts. 

Flux Power Holdings stated that this additional channel for lithium technology is a natural extension for the Company in its broader goal of serving a variety of industrial markets.  In doing so, the Company expects to capture the benefits of building bigger and more expensive equipment. This includes better economies of scale and higher financial margins.

Regarding the Flux battery model: LiFT-24V, it offers up to a 5 times longer lifespan andup to a 25 percent longer run time. It also offers higher sustained power during every work shift. It is maintenance-free and fewer batteries are required for multi-shift applications.

Flux Power Holdings, Inc. (FLUX), closed Friday's trading session at $0.50, even for the day, on 1,100 volume with 3 trades. The average volume for the last 60 days is 237 and the stock's 52-week low/high is $0.151/$1.00.


The QualityStocks
Company Corner


ChineseInvestors.com, Inc. (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com, Inc. (CIIX). Today, ChineseInvestors.com, Inc. closed trading at $0.5345, up 1.81%, on 222,559 volume with 92 trades. The stock’s average daily volume over the past 60 days is 72,206 and its 52-week low/high is $0.32/$2.75.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring ChineseInvestors.com, Inc. (OTCQB: CIIX), a client of NNW recognizing unprecedented opportunities in the U.S. cannabis industry and laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products. The publication is titled, "Cannabinoid Consumer Market Booming as CBD Enjoys Growth in Public Sentiment." It discusses various cannabis-based public companies determined to expand with the booming cannabis market. To view the full publication, visit: https://www.networknewswire.com/cannabinoid-consumer-market-booming-cbd-enjoys-growth-public-sentiment/

Founded in 1999, ChineseInvestors.com, Inc. (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer

ChineseInvestors.com, Inc. Blog

ChineseInvestors.com, Inc. News:

NetworkNewsWire Announces Publication on Cannabis Industry Forecasts and Public Companies Advancing in the Market

Alan Klitenic, Director of Investor Relations for ChineseInvestors.com, Discusses Recent CIIX News and Industry Trends in a New Audio Interview with SmallCapVoice.com

ChineseInvestors.com, Inc.'s Wholly Owned Foreign Enterprise, CBD Biotechnology Co. Ltd., Completes the Record Filing Process with the China FDA, Expects to Launch its Hemp Infused Skin Care Line in October

ORHub, Inc. (ORHB)

The QualityStocks Daily Newsletter would like to spotlight ORHub, Inc. (ORHB). Today, ORHub, Inc. closed trading at $0.547, up 0.37%, on 50,300 volume with 12 trades. The stock’s average daily volume over the past 60 days is 63,514 and its 52-week low/high is $0.20/$2.09.

ORHub, Inc. (ORHB), a medical software company focused on delivering case-based data analytics at the speed of surgery, today announced that its Chief Operating Officer, Cyrus P. Olsen, will be taking a leave of absence, effective as of September 19. For personal reasons, Dr. Olsen will leave his role as COO, but act in an advisory role to the company through the end of the year.

ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.

The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.

Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.

Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.

In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.

ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.

The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.

ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.

Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care. Disclaimer

ORHub, Inc. Blog

ORHub, Inc. News:

ORHub (ORHB) Announces COO Leave of Absence

ORHub (ORHB) Joins ICHOM TechHub to Propel Value-Driven Improvements in Healthcare

ORHub, Inc. Announces Major Expansion of Operations with Launch and Adoption of Orthopedic Service Lines


The QualityStocks Daily Newsletter would like to spotlight ABcann Global (ABCCF). Today, ABcann Global closed trading at $0.7128, off by 0.78%, on 182,237 volume with 162 trades. The stock’s average daily volume over the past 60 days is 116,040 and its 52-week low/high is $0.6171/$0.90.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring ABcann Global (TSX VENTURE: ABCN) (OTCQB: ABCCF), a client of NNW that is a globally licensed, cost efficient producer of premium quality organic standardized medicinal cannabis. The publication, titled, "Production Bottleneck Spells Opportunity for Canada's Cannabis Producers," highlights the licensed producers that are expanding to keep up with the demand for medical marijuana in Canada. To view the full publication, visit: https://www.networknewswire.com/production-bottleneck-spells-opportunity-canadas-cannabis-producers/

ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF) ABcann Medicinals, Inc. is a globally licensed, cost efficient producer of premium quality organic standardized medicinal cannabis. One of the earliest licensed Canadian medical marijuana producers under Canada's federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), ABcann has five years of operating experience in the burgeoning medical marijuana space. The company currently owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario. Additionally, ABcann owns 65 acres of real estate with proper zoning and existing infrastructure in place to support the construction of another production facility of up to one million square feet.

In a November 2016 report, market research firm Canaccord Genuity Group forecasted that the medical marijuana market in Canada could see sales in excess of $8 billion by 2024, creating a sizable opportunity for the country's licensed producers (LPs). The research firm also noted that the "rigorous process of becoming a licensed producer of cannabis in Canada imposes significant barriers to entry and there will be a shortfall of supply in a legalized market in the short-term." This market barrier serves as a strategic advantage for ABcann as it prepares for its highly-anticipated IPO, which is currently scheduled for April 2017.

Canaccord's synopsis of the Canadian cannabis industry is supported by recent market activity, as companies sporting one of the illustrious Canadian government licenses for medicinal production have recorded strong growth following IPO. Canopy Growth (OTC: TWMJ), one of the largest fully-licensed Canadian marijuana growers, saw share prices skyrocket by more than 700 percent in the months following its initial offering. Aphria Inc. (OTC: APHQF), another licensed grower, climbed by more than 900 percent following its IPO. Other companies that have recorded huge growth since going public include Aurora Cannabis (OTC: ACBFF), climbing nearly 900 percent, and SupremePharma (OTC: SPRWF), which soared more than 1,300 percent.

With these market trends in mind, ABcann's impending IPO is one that prospective investors in the marijuana sector will want to explore. Recalls from some of the biggest players in the Canadian cannabis industry have highlighted the considerable learning curve that LPs face in today's market, which makes ABcann's proven track record in the market all the more noteworthy. The company has built a reputation over the years for its best-in-class standardized approach to growing cannabis, including the thoughtful omission of pesticides and a computer monitored growing technique that allows ABcann to minimize the risks of variance in its yields and ensure the creation of consistently high-quality products.

This technique, which the company calls the ABcann Advantage, has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with ABcann's current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry. This global growth potential is illustrated by ABcann's partnership with Israel's Syqe Medical, producer of the world's first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting the company's production facility, Perry Davidson, founder of Syqe Medical, noted that ABcann's production technologies put it "in a class with the best in the world" in its ability to produce standardized pharmaceutical grade cannabis.

ABcann's entry into the public sector is being guided by a seasoned management team, board of directors and advisory board that feature well over a century of combined industry experience. Ken Clement, the company' founder and executive chairman, has been the key component and driving force behind ABcann's development since its inception. His vision of standardized production and dosage sets ABcann apart in the medical cannabis sector. Clement is joined on the company's management team by CEO Aaron Keay. Keay brings more than a decade of capital markets experience to ABcann, having played a role in raising approximately $250 million for public and private market issuers.

Notably, ABcann also has access to the 'Father of Cannabis Research', Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC), and he has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, ABcann is well-positioned to compete in the rapidly-expanding Canadian medicinal cannabis industry. These factors, along with the company's ongoing global expansion into the European, Australian and Israeli markets, show why ABcann Medicinals' upcoming public offering fits the bill as "Canada's Next Medical Marijuana IPO." Disclaimer

ABcann Global Blog

ABcann Global News:

NetworkNewsWire Announces Publication on Investment Opportunities in Canada's Cannabis Market

ABcann Global Enters Its Growth Phase (Plus Exclusive Interview) -- CFN Media

NetworkNewsWire Announces Publication on the Operations of Key Players in Canada's Legal Marijuana Market

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE). Today, Global Payout, Inc. closed trading at $0.0183, off by 4.19%, on 1,023,069 volume with 57 trades. The stock’s average daily volume over the past 60 days is 2,277,572, and its 52-week low/high is $0.0077/$0.04.

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout's fully configurable "banking-in-a-box" web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today's banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout's management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and "high-risk" market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and "high-risk" enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions. Disclaimer

Global Payout, Inc. Company Blog

Global Payout, Inc. News:

MoneyTrac Technology, Inc. Establishes Key Industry Connections Through Participation in the 4th Annual Cannabis World Congress & Business Exposition in Los Angeles, CA

MoneyTrac Technology, Inc. Establishes Key Industry Connections Through Participation in the 4th Annual Cannabis World Congress & Business Exposition in Los Angeles, CA

Global Payout's Moneytrac Technology Inc. Signs LOI with Renowned Marijuana Technology Company, BlazeNow, Inc.

InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.35, up 0.86%, on 305,389 volume with 198 trades. The stock’s average daily volume over the past 60 days is 350,474, and its 52-week low/high is $0.073/$0.72.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

InMed Pharmaceuticals Added to CSE25 Index

InMed Pharma: A Leader in Cannabinoid Biosynthesis -- CFN Media

InMed Retains Consultant Ben Paterson for Biosynthesis Development


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



(MMRF) +122.22%


MarketClub Analysis
(IZEA) +64.10%


Wall Street Mover
(NETE) +44.72%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251